![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Department of Physical Sciences, Chapman University, Orange, California (M.T.G.); Laboratory of Biomedical Genetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo, Japan (M.M., M.M.T.); Department of Pharmacology, College of Medicine, University of California, Irvine, Irvine, California (D.S., K.Z.A., F.J.E.); and Division of Neural Network, Department of Basic Medical Sciences, University of Tokyo, Tokyo, Japan (T.M.)
We investigated the subtypes of the muscarinic receptor mediating short-term heterologous desensitization in the isolated ileum. Treatment of the ileum from C57BL/6 mice with acetylcholine (30 µM) for 20 min caused a subsequent decrease in contractile sensitivity to both prostaglandin F2
(PGF2
) and the muscarinic agonist, oxotremorine-M. This subsensitivity was characterized by 7- and 3-fold increases in the EC50 values of the agonists, respectively, with no significant effect on the maximal response. The subsensitivity to PGF2
was prevented in both M2 and M3 muscarinic receptor knockout mice. Similarly, the subsensitivity to oxotremorine-M was prevented in M2 knockout mice. Acetylcholine-mediated desensitization of histamine-induced contractions in the guinea pig ileum was inhibited by both M2- and M3-selective muscarinic antagonists with high potency, although careful analysis of the data suggested behavior more consistent with an M2 antagonistic profile. Modeling studies showed that the competitive antagonism of response contingent upon activation of two receptor subtypes should exhibit a pharmacological profile similar to that of the least sensitive signaling pathway. Our results demonstrate that muscarinic agonist-mediated short-term heterologous desensitization of intestinal smooth muscle is contingent upon activation of both M2 and M3 muscarinic receptors and that activation of either receptor by itself is insufficient to cause desensitization.
Address correspondence to: Dr. Frederick J. Ehlert, Department of Pharmacology, University of California, Irvine, Irvine, California 92697-4625. E-mail: fjehlert{at}uci.edu
This article has been cited by other articles:
![]() |
A. S. Braverman, A. S. Tibb, and M. R. Ruggieri Sr M2 and M3 Muscarinic Receptor Activation of Urinary Bladder Contractile Signal Transduction. I. Normal Rat Bladder J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 869 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Ehlert, M. T. Griffin, D. M. Abe, T. H. Vo, M. M. Taketo, T. Manabe, and M. Matsui The M2 Muscarinic Receptor Mediates Contraction through Indirect Mechanisms in Mouse Urinary Bladder J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 368 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Ehlert, J. C.-H. Hsu, K. Leung, A. G. Lee, D. Shehnaz, and M. T. Griffin Comparison of the Antimuscarinic Action of p-Fluorohexahydrosiladifenidol in Ileal and Tracheal Smooth Muscle J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 592 - 600. [Abstract] [Full Text] [PDF] |
||||